In Brief: Genentech's Activase
Executive Summary
Genentech's Activase: GUSTO III results show no statistically significant 30-day mortality benefit for Boehringer- Mannheim's thrombolytic agent Retavase compared to Activase for treatment of acute myocardial infarction. Overall mortality rate for Retavase was 7.43%, compared to Activase's 7.22%, according to data presented at the American College of Cardiology meeting...